{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:19Z","timestamp":1781653999675,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The retina, as an extension of the central nervous system, is highly susceptible to inflammatory and degenerative changes similar to those brain seen in Parkinson\u2019s disease (PD) and Alzheimer\u2019s disease (AD). Annexin A proteins, particularly annexin A1 (AnxA1) and annexin A2 (AnxA2), may play key roles in regulating neuroinflammation and maintaining retinal homeostasis. AnxA1 provides strong anti-inflammatory and pro-resolution actions, limiting cytokine release and promoting a reparative microglial phenotype. AnxA2, which often acts as an S100A10-AnxA2 complex, supports inflammatory resolution through tPA- and TLR4-dependent pathways and contributes to glial stability. In PD, retinal degeneration mirrors brain pathology, and reduced AnxA1 activity may impair the resolution of inflammation. In AD, decreased AnxA1 signalling compromises \u03b2-amyloid clearance and maintains chronic neuroinflammation. However, endogenous release of AnxA1 or therapy with AnxA1-derived peptides is capable of promoting efficient phagocytosis by microglia, clearing the neurotoxic environment in AD brains. Overall, it is possible that coordinated AnxA1\/AnxA2 activity may mitigate retinal damage, improve the removal of toxic aggregates, and preserve vision, highlighting annexin pathways as promising therapeutic targets for retinal degeneration in PD and AD. This makes it an interesting target for study during retinal degeneration in PD and AD.<\/jats:p>","DOI":"10.1186\/s40942-025-00786-y","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:48:21Z","timestamp":1770180501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From brain to eye: Annexin A1 and A2 as a key mediator of retinal neuroinflammation in Parkinson\u2019s and Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-5722","authenticated-orcid":false,"given":"Luiz Philipe","family":"de Souza Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-8696","authenticated-orcid":false,"given":"Caio Vinicius","family":"Saito Regatieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"1","key":"786_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2012.227","volume":"9","author":"A London","year":"2013","unstructured":"London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9(1):44\u201353. https:\/\/doi.org\/10.1038\/nrneurol.2012.227.","journal-title":"Nat Rev Neurol"},{"key":"786_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fnagi.2017.00214","volume":"9","author":"AI Ramirez","year":"2017","unstructured":"Ramirez AI, de Hoz R, Salobrar-Garcia E, Salazar JJ, Rojas B, Ajoy D, L\u00f3pez-Cuenca I, Rojas P, Trivi\u00f1o A, Ram\u00edrez JM. The role of microglia in retinal neurodegeneration: alzheimer\u2019s Disease, Parkinson, and glaucoma. Front Aging Neurosci. 2017;9:214. https:\/\/doi.org\/10.3389\/fnagi.2017.00214.","journal-title":"Front Aging Neurosci"},{"key":"786_CR3","doi-asserted-by":"publisher","first-page":"101273","DOI":"10.1016\/j.preteyeres.2024.101273","volume":"101","author":"BP Gaire","year":"2024","unstructured":"Gaire BP, Koronyo Y, Fuchs DT, Shi H, Rentsendorj A, Danziger R, Vit JP, Mirzaei N, Doustar J, Sheyn J, Hampel H, Vergallo A, Davis MR, Jallow O, Baldacci F, Verdooner SR, Barron E, Mirzaei M, Gupta VK, Graham SL, Tayebi M, Carare RO, Sadun AA, Miller CA, Dumitrascu OM, Lahiri S, Gao L, Black KL, Koronyo-Hamaoui M. Alzheimer\u2019s disease pathophysiology in the retina. Prog Retin Eye Res. 2024;101:101273. https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101273.","journal-title":"Prog Retin Eye Res"},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"108809","DOI":"10.1016\/j.pharmthera.2025.108809","volume":"267","author":"LP de Souza Ferreira","year":"2025","unstructured":"de Souza Ferreira LP, da Silva RA, Borges PP, Xavier LF, Scharf P, Sandri S, Oliani SM, Farsky SHP, Gil CD. Annexin A1 in neurological disorders: neuroprotection and glial modulation. Pharmacol Ther. 2025;267:108809. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108809.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"786_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3390\/antiox13101274","volume":"13","author":"L Ye","year":"2024","unstructured":"Ye L, Zhao J, Xiao Z, Gu W, Liu X, Ajuyo NMC, Min Y, Pei Y, Wang D. Integrative human genetic and cellular analysis of the pathophysiological roles of AnxA2 in alzheimer\u2019s disease. Antioxid (Basel). 2024;13(10):1274. https:\/\/doi.org\/10.3390\/antiox13101274.","journal-title":"Antioxid (Basel)"},{"issue":"4","key":"786_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/glia.22284","volume":"60","author":"D Pineda","year":"2012","unstructured":"Pineda D, Ampurdan\u00e9s C, Medina MG, Serratosa J, Tusell JM, Saura J, Planas AM, Navarro P. Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors. Glia. 2012;60(4):526\u201340. https:\/\/doi.org\/10.1002\/glia.22284.","journal-title":"Glia"},{"issue":"15","key":"786_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/WNR.0000000000001721","volume":"32","author":"DW Li","year":"2021","unstructured":"Li DW, Qi XD, Zhang CH, Sun WP. Annexin A2 degradation contributes to dopaminergic cell apoptosis via regulating p53 in neurodegenerative conditions. NeuroReport. 2021;32(15):1263\u20138. https:\/\/doi.org\/10.1097\/WNR.0000000000001721.","journal-title":"NeuroReport"},{"issue":"3","key":"786_CR8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1172\/JCI124635","volume":"130","author":"S McArthur","year":"2020","unstructured":"McArthur S, Juban G, Gobbetti T, Desgeorges T, Theret M, Gondin J, Toller-Kawahisa JE, Reutelingsperger CP, Chazaud B, Perretti M, Mounier R. Annexin A1 drives macrophage skewing to accelerate muscle regeneration through AMPK activation. J Clin Invest. 2020;130(3):1156\u201367. https:\/\/doi.org\/10.1172\/JCI124635.","journal-title":"J Clin Invest"},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"406273","DOI":"10.1155\/2012\/406273","volume":"2012","author":"N Hedhli","year":"2012","unstructured":"Hedhli N, Falcone DJ, Huang B, Cesarman-Maus G, Kraemer R, Zhai H, Tsirka SE, Santambrogio L, Hajjar KA. The Annexin A2\/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol. 2012;2012:406273. https:\/\/doi.org\/10.1155\/2012\/406273.","journal-title":"J Biomed Biotechnol"},{"issue":"7","key":"786_CR10","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/glia.70018","volume":"73","author":"AP Patton","year":"2025","unstructured":"Patton AP, Krogager TP, Maywood ES, Smyllie NJ, Morris EL, Skehel M, Hastings MH. Multi-Omic analysis reveals astrocytic Annexin-A2 as critical for Network-Level circadian timekeeping in the Suprachiasmatic nucleus. Glia. 2025;73(7):1483\u2013501. https:\/\/doi.org\/10.1002\/glia.70018.","journal-title":"Glia"},{"issue":"6","key":"786_CR11","doi-asserted-by":"publisher","first-page":"e27729","DOI":"10.1016\/j.heliyon.2024.e27729","volume":"10","author":"M He","year":"2024","unstructured":"He M, Xie G, Shen F, Li X. Activation of astrocytes by ANXA2-derived extracellular vesicles from lung cancer cells affects aggressiveness, immunotherapy response and microenvironment of lung cancer. Heliyon. 2024;10(6):e27729. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27729.","journal-title":"Heliyon"},{"issue":"11","key":"786_CR12","doi-asserted-by":"publisher","first-page":"103367","DOI":"10.1016\/j.drudis.2022.103367","volume":"27","author":"R Andr\u00e9 da Silva","year":"2022","unstructured":"Andr\u00e9 da Silva R, Moraes de Paiva Roda V, Philipe de Souza Ferreira L, Oliani SM, Paula Girol A, Gil CD. Annexins as potential targets in ocular diseases. Drug Discov Today. 2022;27(11):103367. https:\/\/doi.org\/10.1016\/j.drudis.2022.103367.","journal-title":"Drug Discov Today"},{"issue":"1","key":"786_CR13","doi-asserted-by":"publisher","first-page":"8757","DOI":"10.1038\/s41467-024-52675-x","volume":"15","author":"M Luo","year":"2024","unstructured":"Luo M, Almeida D, Dallacasagrande V, Hedhli N, Gupta M, D\u2019Amico DJ, Kiss S, Hajjar KA. Annexin A2 promotes proliferative vitreoretinopathy in response to a macrophage inflammatory signal in mice. Nat Commun. 2024;15(1):8757. https:\/\/doi.org\/10.1038\/s41467-024-52675-x.","journal-title":"Nat Commun"},{"issue":"4","key":"786_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1167\/iovs.64.4.33","volume":"64","author":"V Dallacasagrande","year":"2023","unstructured":"Dallacasagrande V, Liu W, Almeida D, Luo M, Hajjar KA. Blockade of Annexin A2 prevents early microvasculopathy in murine models of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2023;64(4):33. https:\/\/doi.org\/10.1167\/iovs.64.4.33.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"786_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41582-022-00618-9","volume":"18","author":"JY Lee","year":"2022","unstructured":"Lee JY, Martin-Bastida A, Murueta-Goyena A, Gabilondo I, Cuenca N, Piccini P, Jeon B. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nat Rev Neurol. 2022;18(4):203\u201320. https:\/\/doi.org\/10.1038\/s41582-022-00618-9.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"786_CR16","doi-asserted-by":"publisher","first-page":"eabc5539","DOI":"10.1126\/sciadv.abc5539","volume":"7","author":"X Li","year":"2021","unstructured":"Li X, Xia Q, Mao M, Zhou H, Zheng L, Wang Y, Zeng Z, Yan L, Zhao Y, Shi J. Annexin-A1 sumoylation regulates microglial polarization after cerebral ischemia by modulating IKK\u03b1 stability via selective autophagy. Sci Adv. 2021;7(4):eabc5539. https:\/\/doi.org\/10.1126\/sciadv.abc5539.","journal-title":"Sci Adv"},{"issue":"1","key":"786_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12974-021-02174-3","volume":"18","author":"X Xu","year":"2021","unstructured":"Xu X, Gao W, Li L, Hao J, Yang B, Wang T, Li L, Bai X, Li F, Ren H, Zhang M, Zhang L, Wang J, Wang D, Zhang J, Jiao L. Annexin A1 protects against cerebral ischemia-reperfusion injury by modulating microglia\/macrophage polarization via FPR2\/ALX-dependent AMPK-mTOR pathway. J Neuroinflammation. 2021;18(1):119. https:\/\/doi.org\/10.1186\/s12974-021-02174-3.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"786_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2009-06-226944","volume":"115","author":"A Swisher","year":"2010","unstructured":"Swisher A, Burton JF, Bacot N, Vogel SM, Feldman SN. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood. 2010;115(3):549\u201358. https:\/\/doi.org\/10.1182\/blood-2009-06-226944.","journal-title":"Blood"},{"issue":"9","key":"786_CR19","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1523\/JNEUROSCI.22-09-03352.2002","volume":"22","author":"CJ Siao","year":"2002","unstructured":"Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through Annexin II. J Neurosci. 2002;22(9):3352\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-09-03352.2002.","journal-title":"J Neurosci"},{"issue":"1","key":"786_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12974-016-0692-6","volume":"13","author":"M Ries","year":"2016","unstructured":"Ries M, Loiola R, Shah UN, Gentleman SM, Solito E, Sastre M. The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-\u03b2 peptide. J Neuroinflammation. 2016;13(1):234. https:\/\/doi.org\/10.1186\/s12974-016-0692-6.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"786_CR21","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/brain\/awab050","volume":"144","author":"M Ries","year":"2021","unstructured":"Ries M, Watts H, Mota BC, Lopez MY, Donat CK, Baxan N, Pickering JA, Chau TW, Semmler A, Gurung B, Aleksynas R, Abelleira-Hervas L, Iqbal SJ, Romero-Molina C, Hernandez-Mir G, d\u2019Amati A, Reutelingsperger C, Goldfinger MH, Gentleman SM, Van Leuven F, Solito E, Sastre M. Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-\u03b2 and Tau pathology. Brain. 2021;144(5):1526\u201341. https:\/\/doi.org\/10.1093\/brain\/awab050.","journal-title":"Brain"},{"issue":"11","key":"786_CR22","doi-asserted-by":"publisher","first-page":"e20240386","DOI":"10.1084\/jem.20240386","volume":"221","author":"Q Cao","year":"2024","unstructured":"Cao Q, Yang S, Wang X, Sun H, Chen W, Wang Y, Gao J, Wu Y, Yang Q, Chen X, Yuan S, Xiao M, Nedergaard M, Huo Y, Liu Q. Transport of \u03b2-amyloid from brain to eye causes retinal degeneration in alzheimer\u2019s disease. J Exp Med. 2024;221(11):e20240386. https:\/\/doi.org\/10.1084\/jem.20240386.","journal-title":"J Exp Med"},{"issue":"11","key":"786_CR23","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1002\/alz.13086","volume":"19","author":"H Shi","year":"2023","unstructured":"Shi H, Koronyo Y, Fuchs DT, Sheyn J, Jallow O, Mandalia K, Graham SL, Gupta VK, Mirzaei M, Kramerov AA, Ljubimov AV, Hawes D, Miller CA, Black KL, Carare RO, Koronyo-Hamaoui M. Retinal arterial A\u03b240 deposition is linked with tight junction loss and cerebral amyloid angiopathy in MCI and AD patients. Alzheimers Dement. 2023;19(11):5185\u201397. https:\/\/doi.org\/10.1002\/alz.13086.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"786_CR24","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1002\/alz.13100","volume":"19","author":"S Adhikari","year":"2023","unstructured":"Adhikari S, Qiao Y, Singer M, Sagare A, Jiang X, Shi Y, Ringman JM, Kashani AH. Retinotopic degeneration of the retina and optic tracts in autosomal dominant alzheimer\u2019s disease. Alzheimers Dement. 2023;19(11):5103\u201313. https:\/\/doi.org\/10.1002\/alz.13100.","journal-title":"Alzheimers Dement"},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3389\/fnins.2020.00921","volume":"14","author":"N Mirzaei","year":"2020","unstructured":"Mirzaei N, Shi H, Oviatt M, Doustar J, Rentsendorj A, Fuchs DT, Sheyn J, Black KL, Koronyo Y, Koronyo-Hamaoui M. Alzheimer\u2019s retinopathy: seeing disease in the eyes. Front Neurosci. 2020;14:921. https:\/\/doi.org\/10.3389\/fnins.2020.00921.","journal-title":"Front Neurosci"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00786-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:03:52Z","timestamp":1781651032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00786-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00786-y","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}